IDEAYA Biosciences Gets $94M In Series B For Oncology Efforts
South San Francisco-based IDEAYA Biosciences, a company developing treatments for cancer, said today that it has raised $94M in a "crossover" Series B financing round. The funding came from BVF Partners L.P., Perceptive Advisors LLC, Nextech Invest Ltd., GV (formerly Google Ventures), Roche Venture Fund, 6 Dimensions Capital, Boxer Capital of the Tavistock Group, and Driehaus Capital Management, LLC, plus curren tinvestors 5AM Ventures, Canaan Partners, Celgene Corporation, WuXi Healthcare Ventures, and Alexandria Venture Investments. IDEAYA Biosciences says it is developing synthetic lethality medicines and immuno-oncology therapies.
posted on Thursday, March 15, 2018 (Link to more information)
Related companies:
Ideaya Biosciences, Inc.
Related stories:
> 3-V Biosciences Finds $20M
> Crown Biosciences Scores $28.8M
> ARMO BioSciences Files For IPO
> Calithera Biosciences Raises $40M
> Cell Biosciences Buys Alpha Innotech, Raises $19M
silicontap.com Home